Floatz Rating
C39/100
Confidence
Indicative
Sponsor
Tanta University
Modality
Small molecule
Development Phase
Early Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
24Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05590117CT.gov Protective Effect of Pentoxifylline Against Chemotherapy Induced Toxicities in Patients With Colorectal Cancer | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Mucositis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pentoxifylline (this asset) | Tanta University | Early P1 | C · 39 |
| Palifermin | Barbara Ann Karmanos Cancer Institute | P3 | BB |
| Fentanyl Sublingual Spray | INSYS Therapeutics Inc | P3 | BB |
| Calcium Phosphate | Children's Oncology Group | P3 | BB |
| Folic Acid | Niels Fristrup | P2 | CCC |
| tk-112690 | Tosk, Inc. | P2 | CCC |
| Everolimus | Emory University | P2 | CCC |
| Methotrexate | University College, London | P1/2 | CCC |
| Pteroylmonoglutamic Acid Hydrolase G2 | University College, London | P1/2 | CCC |
+1 more in the Mucositis cohort
Other indications for Pentoxifylline
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metabolic Dysfunction-Associated Steatohepatitis | — | P4 | BBB · 76 |
| Type 2 Diabetes Mellitus | — | P4 | BB · 68 |
| Peripheral Neuropathy | — | P2/3 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pentoxifylline in Mucositis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pentoxifylline-mucositis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →